JP2010502717A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010502717A5 JP2010502717A5 JP2009527438A JP2009527438A JP2010502717A5 JP 2010502717 A5 JP2010502717 A5 JP 2010502717A5 JP 2009527438 A JP2009527438 A JP 2009527438A JP 2009527438 A JP2009527438 A JP 2009527438A JP 2010502717 A5 JP2010502717 A5 JP 2010502717A5
- Authority
- JP
- Japan
- Prior art keywords
- optionally substituted
- group
- compound according
- compound
- indazol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims 55
- -1 hydroxy, amino, nitro, cyano, guanidino, Amidino, carboxy, sulfo, mercapto, sulfanyl Chemical group 0.000 claims 18
- 125000000217 alkyl group Chemical group 0.000 claims 14
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 12
- 125000001931 aliphatic group Chemical group 0.000 claims 9
- 239000008194 pharmaceutical composition Substances 0.000 claims 9
- 125000003545 alkoxy group Chemical group 0.000 claims 8
- 125000001072 heteroaryl group Chemical group 0.000 claims 8
- 102100036342 Interleukin-1 receptor-associated kinase 1 Human genes 0.000 claims 7
- 101710199015 Interleukin-1 receptor-associated kinase 1 Proteins 0.000 claims 7
- 125000002723 alicyclic group Chemical group 0.000 claims 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 5
- 208000035475 disorder Diseases 0.000 claims 5
- 125000005843 halogen group Chemical group 0.000 claims 5
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 5
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 5
- 238000000034 method Methods 0.000 claims 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 5
- 125000004093 cyano group Chemical group *C#N 0.000 claims 4
- 125000000753 cycloalkyl group Chemical group 0.000 claims 4
- 125000001475 halogen functional group Chemical group 0.000 claims 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 4
- 125000003107 substituted aryl group Chemical group 0.000 claims 4
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims 3
- 125000003368 amide group Chemical group 0.000 claims 3
- 125000003118 aryl group Chemical group 0.000 claims 3
- 125000004076 pyridyl group Chemical group 0.000 claims 3
- NCEXYHBECQHGNR-QZQOTICOSA-N sulfasalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-QZQOTICOSA-N 0.000 claims 3
- 229930105110 Cyclosporin A Natural products 0.000 claims 2
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims 2
- 108010036949 Cyclosporine Proteins 0.000 claims 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 2
- 102000014150 Interferons Human genes 0.000 claims 2
- 108010050904 Interferons Proteins 0.000 claims 2
- UETNIIAIRMUTSM-UHFFFAOYSA-N Jacareubin Natural products CC1(C)OC2=CC3Oc4c(O)c(O)ccc4C(=O)C3C(=C2C=C1)O UETNIIAIRMUTSM-UHFFFAOYSA-N 0.000 claims 2
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 201000004681 Psoriasis Diseases 0.000 claims 2
- 206010040047 Sepsis Diseases 0.000 claims 2
- 206010052779 Transplant rejections Diseases 0.000 claims 2
- 125000002947 alkylene group Chemical group 0.000 claims 2
- 208000026935 allergic disease Diseases 0.000 claims 2
- 150000001408 amides Chemical class 0.000 claims 2
- 208000006673 asthma Diseases 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 229960001265 ciclosporin Drugs 0.000 claims 2
- 239000003246 corticosteroid Substances 0.000 claims 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 2
- 125000000623 heterocyclic group Chemical group 0.000 claims 2
- 229960000598 infliximab Drugs 0.000 claims 2
- 229940079322 interferon Drugs 0.000 claims 2
- 230000001404 mediated effect Effects 0.000 claims 2
- 229960000485 methotrexate Drugs 0.000 claims 2
- 201000006417 multiple sclerosis Diseases 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- 125000000547 substituted alkyl group Chemical group 0.000 claims 2
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims 2
- 229960001940 sulfasalazine Drugs 0.000 claims 2
- NCEXYHBECQHGNR-UHFFFAOYSA-N sulfasalazine Natural products C1=C(O)C(C(=O)O)=CC(N=NC=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-UHFFFAOYSA-N 0.000 claims 2
- 208000024891 symptom Diseases 0.000 claims 2
- UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 claims 2
- AXZVEOQAICRWJY-UHFFFAOYSA-N 1-(4-hydroxycyclohexyl)-2-[[5-(2-methoxyphenyl)-1h-indazol-3-yl]amino]-n-(3-methylbutyl)benzimidazole-5-carboxamide Chemical compound COC1=CC=CC=C1C1=CC=C(NN=C2NC=3N(C4=CC=C(C=C4N=3)C(=O)NCCC(C)C)C3CCC(O)CC3)C2=C1 AXZVEOQAICRWJY-UHFFFAOYSA-N 0.000 claims 1
- QZMAOGLWCNTFCG-UHFFFAOYSA-N 1-(4-hydroxycyclohexyl)-n-(3-methylbutyl)-2-[[5-[2-(trifluoromethoxy)phenyl]-1h-indazol-3-yl]amino]benzimidazole-5-carboxamide Chemical compound N=1NC2=CC=C(C=3C(=CC=CC=3)OC(F)(F)F)C=C2C=1NC1=NC2=CC(C(=O)NCCC(C)C)=CC=C2N1C1CCC(O)CC1 QZMAOGLWCNTFCG-UHFFFAOYSA-N 0.000 claims 1
- RSFJUAJAYHSBHD-UHFFFAOYSA-N 1-cyclohexyl-n-[5-(4-methoxypyridin-3-yl)-1h-indazol-3-yl]-5-(morpholin-4-ylmethyl)benzimidazol-2-amine Chemical compound COC1=CC=NC=C1C1=CC=C(NN=C2NC=3N(C4=CC=C(CN5CCOCC5)C=C4N=3)C3CCCCC3)C2=C1 RSFJUAJAYHSBHD-UHFFFAOYSA-N 0.000 claims 1
- VTJFVOQGGHESGO-UHFFFAOYSA-N 1-cyclohexyl-n-[5-(4-methoxypyridin-3-yl)-1h-indazol-3-yl]-5-(piperidin-1-ylmethyl)benzimidazol-2-amine Chemical compound COC1=CC=NC=C1C1=CC=C(NN=C2NC=3N(C4=CC=C(CN5CCCCC5)C=C4N=3)C3CCCCC3)C2=C1 VTJFVOQGGHESGO-UHFFFAOYSA-N 0.000 claims 1
- 125000004204 2-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C(OC([H])([H])[H])C([H])=C1[H] 0.000 claims 1
- JIDRQSULGLZGQN-UHFFFAOYSA-N 3-[2-[(5-bromo-1h-indazol-3-yl)amino]benzimidazol-1-yl]propan-1-ol Chemical compound C1=CC=C2N(CCCO)C(NC=3C4=CC(Br)=CC=C4NN=3)=NC2=C1 JIDRQSULGLZGQN-UHFFFAOYSA-N 0.000 claims 1
- FETDUDQELDASEU-UHFFFAOYSA-N 3-[2-[[5-(4-methoxypyridin-3-yl)-1h-indazol-3-yl]amino]benzimidazol-1-yl]propan-1-ol Chemical compound COC1=CC=NC=C1C1=CC=C(NN=C2NC=3N(C4=CC=CC=C4N=3)CCCO)C2=C1 FETDUDQELDASEU-UHFFFAOYSA-N 0.000 claims 1
- XNNSMLBQCJOFTI-UHFFFAOYSA-N 4-[5-(hydroxymethyl)-2-[[5-(4-methoxypyridin-3-yl)-1h-indazol-3-yl]amino]benzimidazol-1-yl]cyclohexan-1-ol Chemical compound COC1=CC=NC=C1C1=CC=C(NN=C2NC=3N(C4=CC=C(CO)C=C4N=3)C3CCC(O)CC3)C2=C1 XNNSMLBQCJOFTI-UHFFFAOYSA-N 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- XHVAWZZCDCWGBK-WYRLRVFGSA-M Aurothioglucose Chemical compound OC[C@H]1O[C@H](S[Au])[C@H](O)[C@@H](O)[C@@H]1O XHVAWZZCDCWGBK-WYRLRVFGSA-M 0.000 claims 1
- 206010010356 Congenital anomaly Diseases 0.000 claims 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims 1
- VVNCNSJFMMFHPL-VKHMYHEASA-N D-penicillamine Chemical compound CC(C)(S)[C@@H](N)C(O)=O VVNCNSJFMMFHPL-VKHMYHEASA-N 0.000 claims 1
- 108010008165 Etanercept Proteins 0.000 claims 1
- 108010072051 Glatiramer Acetate Proteins 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 206010061598 Immunodeficiency Diseases 0.000 claims 1
- 208000029462 Immunodeficiency disease Diseases 0.000 claims 1
- 208000001132 Osteoporosis Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- VDRMHRQQXLXAAC-UHFFFAOYSA-N [1-(4-hydroxycyclohexyl)-2-[[5-(2-methoxyphenyl)-1h-indazol-3-yl]amino]benzimidazol-5-yl]-pyrrolidin-1-ylmethanone Chemical compound COC1=CC=CC=C1C1=CC=C(NN=C2NC=3N(C4=CC=C(C=C4N=3)C(=O)N3CCCC3)C3CCC(O)CC3)C2=C1 VDRMHRQQXLXAAC-UHFFFAOYSA-N 0.000 claims 1
- RCDOOVVHRGUAKF-UHFFFAOYSA-N [1-cyclohexyl-2-[[5-(4-methoxypyridin-3-yl)-1h-indazol-3-yl]amino]benzimidazol-5-yl]methanol Chemical compound COC1=CC=NC=C1C1=CC=C(NN=C2NC=3N(C4=CC=C(CO)C=C4N=3)C3CCCCC3)C2=C1 RCDOOVVHRGUAKF-UHFFFAOYSA-N 0.000 claims 1
- KEUZEVMRSCNJPS-UHFFFAOYSA-N [1-cyclohexyl-2-[[5-[3-(methoxymethyl)phenyl]-1h-indazol-3-yl]amino]benzimidazol-5-yl]methanol Chemical compound COCC1=CC=CC(C=2C=C3C(NC=4N(C5=CC=C(CO)C=C5N=4)C4CCCCC4)=NNC3=CC=2)=C1 KEUZEVMRSCNJPS-UHFFFAOYSA-N 0.000 claims 1
- QIDYRHBYOJBERW-UHFFFAOYSA-N [2-[[5-(3-aminophenyl)-1h-indazol-3-yl]amino]-3-cyclohexylbenzimidazol-5-yl]methanol Chemical compound NC1=CC=CC(C=2C=C3C(NC=4N(C5=CC(CO)=CC=C5N=4)C4CCCCC4)=NNC3=CC=2)=C1 QIDYRHBYOJBERW-UHFFFAOYSA-N 0.000 claims 1
- PGSYKHBFXWTSGP-UHFFFAOYSA-N [2-[[5-(4-methoxypyridin-3-yl)-1h-indazol-3-yl]amino]-1-phenylbenzimidazol-5-yl]methanol Chemical compound COC1=CC=NC=C1C1=CC=C(NN=C2NC=3N(C4=CC=C(CO)C=C4N=3)C=3C=CC=CC=3)C2=C1 PGSYKHBFXWTSGP-UHFFFAOYSA-N 0.000 claims 1
- FHEAIOHRHQGZPC-KIWGSFCNSA-N acetic acid;(2s)-2-amino-3-(4-hydroxyphenyl)propanoic acid;(2s)-2-aminopentanedioic acid;(2s)-2-aminopropanoic acid;(2s)-2,6-diaminohexanoic acid Chemical compound CC(O)=O.C[C@H](N)C(O)=O.NCCCC[C@H](N)C(O)=O.OC(=O)[C@@H](N)CCC(O)=O.OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 FHEAIOHRHQGZPC-KIWGSFCNSA-N 0.000 claims 1
- 125000002252 acyl group Chemical group 0.000 claims 1
- 125000003435 aroyl group Chemical group 0.000 claims 1
- 125000003710 aryl alkyl group Chemical group 0.000 claims 1
- 125000004104 aryloxy group Chemical group 0.000 claims 1
- AUJRCFUBUPVWSZ-XTZHGVARSA-M auranofin Chemical compound CCP(CC)(CC)=[Au]S[C@@H]1O[C@H](COC(C)=O)[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@H]1OC(C)=O AUJRCFUBUPVWSZ-XTZHGVARSA-M 0.000 claims 1
- 229960005207 auranofin Drugs 0.000 claims 1
- 229960001799 aurothioglucose Drugs 0.000 claims 1
- 230000001363 autoimmune Effects 0.000 claims 1
- 229960002170 azathioprine Drugs 0.000 claims 1
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 claims 1
- 125000002619 bicyclic group Chemical group 0.000 claims 1
- 125000001246 bromo group Chemical group Br* 0.000 claims 1
- 239000004202 carbamide Substances 0.000 claims 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 1
- 230000001413 cellular effect Effects 0.000 claims 1
- 229940111134 coxibs Drugs 0.000 claims 1
- 125000004122 cyclic group Chemical group 0.000 claims 1
- 125000000000 cycloalkoxy group Chemical group 0.000 claims 1
- HPXRVTGHNJAIIH-UHFFFAOYSA-N cyclohexanol Chemical compound OC1CCCCC1 HPXRVTGHNJAIIH-UHFFFAOYSA-N 0.000 claims 1
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 claims 1
- 229960004397 cyclophosphamide Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000004064 dysfunction Effects 0.000 claims 1
- 229960000403 etanercept Drugs 0.000 claims 1
- MYSIISRDNSWBDA-UHFFFAOYSA-N ethyl 1-(4-hydroxycyclohexyl)-2-[[5-(4-methoxypyridin-3-yl)-1h-indazol-3-yl]amino]benzimidazole-5-carboxylate Chemical compound N=1NC2=CC=C(C=3C(=CC=NC=3)OC)C=C2C=1NC1=NC2=CC(C(=O)OCC)=CC=C2N1C1CCC(O)CC1 MYSIISRDNSWBDA-UHFFFAOYSA-N 0.000 claims 1
- 229960003776 glatiramer acetate Drugs 0.000 claims 1
- 239000003862 glucocorticoid Substances 0.000 claims 1
- 230000010247 heart contraction Effects 0.000 claims 1
- 125000004475 heteroaralkyl group Chemical group 0.000 claims 1
- 125000005553 heteroaryloxy group Chemical group 0.000 claims 1
- 229910052739 hydrogen Inorganic materials 0.000 claims 1
- 239000001257 hydrogen Substances 0.000 claims 1
- XXSMGPRMXLTPCZ-UHFFFAOYSA-N hydroxychloroquine Chemical compound ClC1=CC=C2C(NC(C)CCCN(CCO)CC)=CC=NC2=C1 XXSMGPRMXLTPCZ-UHFFFAOYSA-N 0.000 claims 1
- 229960004171 hydroxychloroquine Drugs 0.000 claims 1
- 125000002962 imidazol-1-yl group Chemical group [*]N1C([H])=NC([H])=C1[H] 0.000 claims 1
- 230000007813 immunodeficiency Effects 0.000 claims 1
- 230000004968 inflammatory condition Effects 0.000 claims 1
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 claims 1
- 229960001428 mercaptopurine Drugs 0.000 claims 1
- KBOPZPXVLCULAV-UHFFFAOYSA-N mesalamine Chemical compound NC1=CC=C(O)C(C(O)=O)=C1 KBOPZPXVLCULAV-UHFFFAOYSA-N 0.000 claims 1
- 229960004963 mesalazine Drugs 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 125000001064 morpholinomethyl group Chemical group [H]C([H])(*)N1C([H])([H])C([H])([H])OC([H])([H])C1([H])[H] 0.000 claims 1
- 206010028417 myasthenia gravis Diseases 0.000 claims 1
- CFSUYKKSSWNBCA-UHFFFAOYSA-N n-cyclopentyl-1-(4-hydroxycyclohexyl)-2-[[5-(2-methoxyphenyl)-1h-indazol-3-yl]amino]benzimidazole-5-carboxamide Chemical compound COC1=CC=CC=C1C1=CC=C(NN=C2NC=3N(C4=CC=C(C=C4N=3)C(=O)NC3CCCC3)C3CCC(O)CC3)C2=C1 CFSUYKKSSWNBCA-UHFFFAOYSA-N 0.000 claims 1
- OYBSTTITNAOGPL-UHFFFAOYSA-N n-cyclopentyl-1-(4-hydroxycyclohexyl)-2-[[5-[2-(trifluoromethoxy)phenyl]-1h-indazol-3-yl]amino]benzimidazole-5-carboxamide Chemical compound C1CC(O)CCC1N1C2=CC=C(C(=O)NC3CCCC3)C=C2N=C1NC1=NNC2=CC=C(C=3C(=CC=CC=3)OC(F)(F)F)C=C12 OYBSTTITNAOGPL-UHFFFAOYSA-N 0.000 claims 1
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 238000007911 parenteral administration Methods 0.000 claims 1
- 229960001639 penicillamine Drugs 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 claims 1
- SRJOCJYGOFTFLH-UHFFFAOYSA-M piperidine-4-carboxylate Chemical compound [O-]C(=O)C1CCNCC1 SRJOCJYGOFTFLH-UHFFFAOYSA-M 0.000 claims 1
- 230000034190 positive regulation of NF-kappaB transcription factor activity Effects 0.000 claims 1
- 230000002062 proliferating effect Effects 0.000 claims 1
- 125000005415 substituted alkoxy group Chemical group 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
- NVBFHJWHLNUMCV-UHFFFAOYSA-N sulfamide Chemical compound NS(N)(=O)=O NVBFHJWHLNUMCV-UHFFFAOYSA-N 0.000 claims 1
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 claims 1
- 229940124530 sulfonamide Drugs 0.000 claims 1
- 150000003456 sulfonamides Chemical class 0.000 claims 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 238000011200 topical administration Methods 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US84280106P | 2006-09-07 | 2006-09-07 | |
| PCT/US2007/019588 WO2008030584A2 (en) | 2006-09-07 | 2007-09-07 | Indazole derivatives as modulators of interleukin- 1 receptor-associated kinase |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010502717A JP2010502717A (ja) | 2010-01-28 |
| JP2010502717A5 true JP2010502717A5 (https=) | 2011-01-20 |
Family
ID=39157878
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009527438A Pending JP2010502717A (ja) | 2006-09-07 | 2007-09-07 | インターロイキン１受容体関連キナーゼの調節物質 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US8293923B2 (https=) |
| EP (1) | EP2061786A2 (https=) |
| JP (1) | JP2010502717A (https=) |
| KR (1) | KR20090049076A (https=) |
| CN (1) | CN101616910A (https=) |
| AU (1) | AU2007292929A1 (https=) |
| BR (1) | BRPI0716549A2 (https=) |
| CA (1) | CA2663100A1 (https=) |
| IL (1) | IL197274A0 (https=) |
| MX (1) | MX2009002377A (https=) |
| NO (1) | NO20091326L (https=) |
| NZ (1) | NZ575410A (https=) |
| RU (1) | RU2459821C2 (https=) |
| WO (1) | WO2008030584A2 (https=) |
| ZA (1) | ZA200901529B (https=) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2243481A1 (en) * | 2009-04-24 | 2010-10-27 | PamGene B.V. | Irak kinase family as novel drug target for Alzheimer |
| RU2632900C2 (ru) * | 2010-11-19 | 2017-10-11 | Лиганд Фармасьютикалс Инкорпорейтед | Гетероциклические амины и их применение |
| US9353087B2 (en) | 2012-06-08 | 2016-05-31 | Biogen Ma Inc. | Inhibitors of Bruton's tyrosine kinase |
| EP2903613B1 (en) | 2012-10-08 | 2017-11-22 | Merck Sharp & Dohme Corp. | Pyrazole derivatives useful as inhibitors of irak4 activity |
| WO2014058685A1 (en) | 2012-10-08 | 2014-04-17 | Merck Sharp & Dohme Corp. | Inhibitors of irak4 activity |
| EP2746259A1 (en) | 2012-12-21 | 2014-06-25 | Basf Se | Substituted [1,2,4]triazole and imidazole compounds |
| EP2746260A1 (en) | 2012-12-21 | 2014-06-25 | Basf Se | Substituted [1,2,4]triazole and imidazole compounds |
| HUE032863T2 (en) * | 2013-02-07 | 2017-11-28 | Merck Patent Gmbh | Piridazinonamid derivatives |
| HRP20171302T1 (hr) * | 2013-02-07 | 2017-10-20 | Merck Patent Gmbh | Makrociklički derivati piridazinona |
| WO2015006181A1 (en) | 2013-07-11 | 2015-01-15 | Merck Sharp & Dohme Corp. | Substituted amidopyrazole inhibitors of interleukin receptor-associated kinases (irak-4) |
| TWI667233B (zh) * | 2013-12-19 | 2019-08-01 | 德商拜耳製藥公司 | 新穎吲唑羧醯胺，其製備方法、含彼等之醫藥製劑及其製造醫藥之用途 |
| EP3092226B1 (en) * | 2014-01-10 | 2019-03-13 | Aurigene Discovery Technologies Limited | Indazole compounds as irak4 inhibitors |
| LT3466955T (lt) * | 2014-01-13 | 2021-02-25 | Aurigene Discovery Technologies Limited | Oksazol[4,5-b]piridino ir tiazol[4,5-b]piridino darinių, kaip irak4 inhibitorių, skirtų vėžio gydymui, gamybos būdas |
| AU2015275730A1 (en) * | 2014-06-20 | 2016-12-15 | Aurigene Discovery Technologies Limited | Substituted indazole compounds as IRAK4 inhibitors |
| JO3705B1 (ar) | 2014-11-26 | 2021-01-31 | Bayer Pharma AG | إندازولات مستبدلة جديدة، عمليات لتحضيرها، مستحضرات دوائية تحتوي عليها واستخدامها في إنتاج أدوية |
| TW201702218A (zh) | 2014-12-12 | 2017-01-16 | 美國杰克森實驗室 | 關於治療癌症、自體免疫疾病及神經退化性疾病之組合物及方法 |
| US10807983B2 (en) | 2015-03-16 | 2020-10-20 | Ligand Pharmaceuticals, Inc. | Imidazo-fused heterocycles and uses thereof |
| EP3195865A1 (de) | 2016-01-25 | 2017-07-26 | Bayer Pharma Aktiengesellschaft | Kombinationen von irak4 inhibitoren und btk inhibitoren |
| TW201701879A (zh) | 2015-04-30 | 2017-01-16 | 拜耳製藥公司 | Ｉｒａｋ４抑制劑組合 |
| WO2017148902A1 (de) | 2016-03-03 | 2017-09-08 | Bayer Pharma Aktiengesellschaft | Neue 2-substituierte indazole, verfahren zu ihrer herstellung, pharmazeutische präparate die diese enthalten, sowie deren verwendung zur herstellung von arzneimitteln |
| EP3219329A1 (en) | 2016-03-17 | 2017-09-20 | Bayer Pharma Aktiengesellschaft | Combinations of copanlisib |
| EP3448849B1 (en) | 2016-04-29 | 2020-05-13 | Bayer Pharma Aktiengesellschaft | Synthesis of indazoles |
| WO2017186689A1 (en) | 2016-04-29 | 2017-11-02 | Bayer Pharma Aktiengesellschaft | Synthesis of indazoles |
| MX394560B (es) | 2016-06-01 | 2025-03-24 | Bayer Pharma AG | Uso de indazoles sustituidos para el tratamiento y la prevencion de enfermedades en animales. |
| CN106222183B (zh) * | 2016-07-25 | 2019-11-08 | 南通大学 | 靶向人irak1基因的小干扰rna及其应用 |
| TW202340194A (zh) | 2017-02-16 | 2023-10-16 | 美商基利科學股份有限公司 | 吡咯并[1,2-b]嗒𠯤衍生物 |
| EP3600270B1 (en) | 2017-03-31 | 2023-06-14 | Aurigene Oncology Limited | Compounds and compositions for treating hematological disorders |
| CN111194319A (zh) | 2017-10-19 | 2020-05-22 | 拜耳动物保健有限责任公司 | 稠合的杂芳族吡咯烷酮类化合物用于治疗和预防动物中的疾病的用途 |
| HUE067356T2 (hu) | 2017-10-31 | 2024-10-28 | Curis Inc | IRAK4 inhibitor és BCL-2 inhibitor kombinációban, rák kezelésére való felhasználásra |
| WO2019111218A1 (en) | 2017-12-08 | 2019-06-13 | Cadila Healthcare Limited | Novel heterocyclic compounds as irak4 inhibitors |
| TWI842978B (zh) * | 2018-07-13 | 2024-05-21 | 美商基利科學股份有限公司 | 衍生物 |
| EP3876939A4 (en) | 2018-11-07 | 2022-08-10 | Dana-Farber Cancer Institute, Inc. | Benzothiazole derivatives and 7-aza-benzothiazole derivatives as janus kinase 2 inhibitors and uses thereof |
| EP3877371A4 (en) | 2018-11-07 | 2022-07-27 | Dana-Farber Cancer Institute, Inc. | IMIDAZOPYRIDINE DERIVATIVES AND AZA-IMIDAZOPYRIDINE DERIVATIVES AS JANUS KINASE 2 INHIBITORS AND USES THEREOF |
| US12522583B2 (en) | 2018-11-07 | 2026-01-13 | Dana-Farber Cancer Institute, Inc. | Benzimidazole derivatives and aza-benzimidazole derivatives as Janus kinase 2 inhibitors and uses thereof |
| US20230002361A1 (en) * | 2019-06-27 | 2023-01-05 | Biogen Ma Inc. | 2h-indazole derivatives and their use in the treatment of disease |
| US11691963B2 (en) | 2020-05-06 | 2023-07-04 | Ajax Therapeutics, Inc. | 6-heteroaryloxy benzimidazoles and azabenzimidazoles as JAK2 inhibitors |
| US12043632B2 (en) | 2020-12-23 | 2024-07-23 | Ajax Therapeutics, Inc. | 6-heteroaryloxy benzimidazoles and azabenzimidazoles as JAK2 inhibitors |
| EP4319750A4 (en) | 2021-04-08 | 2025-02-26 | Curis, Inc. | COMBINATION THERAPIES FOR THE TREATMENT OF CANCER |
| CN115710253B (zh) * | 2021-08-23 | 2024-07-02 | 上海交通大学 | 一类含有氨基苯并咪唑类衍生物及其制备和用途 |
| WO2023086319A1 (en) | 2021-11-09 | 2023-05-19 | Ajax Therapeutics, Inc. | 6-he tero aryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors |
| US12162881B2 (en) | 2021-11-09 | 2024-12-10 | Ajax Therapeutics, Inc. | Forms and compositions of inhibitors of JAK2 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8716111D0 (en) * | 1987-07-08 | 1987-08-12 | Unilever Plc | Edible plastic dispersion |
| ES2200163T3 (es) * | 1996-11-15 | 2004-03-01 | Darwin Discovery Limited | Aril-carboxamidas biciclicas y su utilizacion terapeutica. |
| AU6870098A (en) * | 1997-03-31 | 1998-10-22 | Du Pont Merck Pharmaceutical Company, The | Indazoles of cyclic ureas useful as hiv protease inhibitors |
| DK1194425T3 (da) * | 1999-06-23 | 2005-11-21 | Aventis Pharma Gmbh | Substituerede benzimidazoler |
| US7132438B2 (en) | 2001-10-09 | 2006-11-07 | Amgen Inc. | Benzimidazole derivatives |
| WO2003082272A1 (en) | 2002-03-29 | 2003-10-09 | Chiron Corporation | Substituted benzazoles and use thereof as raf kinase inhibitors |
-
2007
- 2007-09-07 EP EP07837920A patent/EP2061786A2/en not_active Withdrawn
- 2007-09-07 US US12/440,163 patent/US8293923B2/en not_active Expired - Fee Related
- 2007-09-07 MX MX2009002377A patent/MX2009002377A/es not_active Application Discontinuation
- 2007-09-07 CN CN200780041379A patent/CN101616910A/zh active Pending
- 2007-09-07 RU RU2009112598/04A patent/RU2459821C2/ru not_active IP Right Cessation
- 2007-09-07 CA CA002663100A patent/CA2663100A1/en not_active Abandoned
- 2007-09-07 AU AU2007292929A patent/AU2007292929A1/en not_active Abandoned
- 2007-09-07 KR KR1020097006123A patent/KR20090049076A/ko not_active Ceased
- 2007-09-07 WO PCT/US2007/019588 patent/WO2008030584A2/en not_active Ceased
- 2007-09-07 BR BRPI0716549-8A2A patent/BRPI0716549A2/pt not_active IP Right Cessation
- 2007-09-07 JP JP2009527438A patent/JP2010502717A/ja active Pending
- 2007-09-07 NZ NZ575410A patent/NZ575410A/en not_active IP Right Cessation
-
2009
- 2009-02-26 IL IL197274A patent/IL197274A0/en unknown
- 2009-03-03 ZA ZA200901529A patent/ZA200901529B/xx unknown
- 2009-04-01 NO NO20091326A patent/NO20091326L/no not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010502717A5 (https=) | ||
| RU2009112598A (ru) | Модуляторы киназы, ассоциированной с рецептором интерлейкина-1 | |
| JP5529827B2 (ja) | ＴＮＦαシグナル伝達のモジュレータ | |
| JP2012523457A5 (https=) | ||
| JP5468578B2 (ja) | インテグリンのその受容体への結合を阻害するプロパン酸誘導体 | |
| ES2381589T3 (es) | Aminometil-4-imidazoles | |
| JP2007524696A5 (https=) | ||
| JP2011503068A5 (https=) | ||
| RU2004117545A (ru) | Аминопиримидины и пиридины | |
| SK83594A3 (en) | Imidazole derivatives, method of their preparation, their use for production of pharmaceutical compositions with their contents | |
| KR20070107075A (ko) | Ｃｘｃｒ３ 길항제 활성을 갖는 신규의 헤테로사이클릭치환된 피리딘 또는 페닐 화합물 | |
| IL160522A (en) | 1h - imidazole derivatives having cb1 agonistic, cb1 partial agonistic or cb1-antagonistic activity | |
| JP2022550099A5 (https=) | ||
| Rani et al. | Trisubstituted imidazole synthesis: A review | |
| Rani et al. | Imidazole and derivatives drugs synthesis: a review | |
| AU2009204358A1 (en) | Substituted-aryl-2-phenylethyl-1H-imidazole compounds as subtype selective modulators of alpha 2B and/or alpha 2C adrenergic receptors | |
| JP2007530570A5 (https=) | ||
| US9487501B2 (en) | Pyrazole carboxamide compounds and uses thereof | |
| RU2011105059A (ru) | Применение производных пиримидиламинобензамида для лечения фиброза | |
| HUP0303038A2 (hu) | Szubsztituált azolszármazékok mint kortikotropin releasing faktor inhibitorok, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk | |
| JP2007532654A5 (https=) | ||
| JPWO1994002472A1 (ja) | チアゾリン誘導体 | |
| Shrivastava et al. | Divers pharmacological significance of imidazole derivatives-A review | |
| EP1628968B1 (en) | 4-imidazolin-2-one compounds | |
| JP2008514665A5 (https=) |